I agree. This could easily double by the next report. As well as continued improvements in all operations, I am expecting a big positive revaluation of company assets at the next report. After all, dermatology was written down from about $90M in Dec 2022 to $20M in June 23 on the basis of poor returns, given that this operating unit has already delivered over A$13 in direct contribution over the first 4 months I expect this asset to be revalued significantly.
MYX Price at posting:
$5.84 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)